Analysis of CRBSI Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter
Analysis of CRBSI (Catheter-Related Blood Stream Infection) Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
This is a U.S. multi - centre, prospective, non-randomized post approval registry. Approximately one hundred and twenty patients will be implanted with a NexSite HD catheter at four to eight U.S. sites where hemodialysis catheters are routinely implanted. Each site may enrol a maximum of 50 patients. Enrolled patients will be followed from device placement to device removal or 180 days post device placement. Patients will be enrolled once only.
The primary endpoint is CRBSI rate related to the NexSite HD catheter. Determination of infection will be decided by the investigator and if necessary adjudicated by the CEC (Clinical Events Committee) based on blood culture results, regardless of whether the catheter is removed.
Secondary endpoints for the study are
- Successful placement and continued use of the NexSite HD device designed for use in patients requiring long term hemodialysis.
- Healing of catheter exit site
- Tunnel Infections
- Exit site infections
- Early non-infectious complications associated with CVCs
- Late non-infectious complications associated with Central Venous Catheters
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
North Carolina
-
Greenville, North Carolina, Stati Uniti, 27834
- Eastern Nephrology Associates
-
New Bern, North Carolina, Stati Uniti, 28542
- Eastern Nephology Associates
-
Raleigh, North Carolina, Stati Uniti, 27610
- Capital Nephrology Associates
-
-
South Carolina
-
Orangeburg, South Carolina, Stati Uniti, 29118
- South Carolina Nephrology and Hypertension Center Inc
-
-
Texas
-
Lubbock, Texas, Stati Uniti, 79416
- Lubbock Vascular Access Centre
-
San Antonio, Texas, Stati Uniti, 78215
- Renal Associates
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- The patient shall be 18 - 80 years old.
- The patient requires the placement of a long term tunnelled HD catheter for administration of hemodialysis.
- The patient has anticipated survival in excess of 90 days from the anticipated date of catheter placement.
- The patient has the ability to understand the research subject information and sign a written Informed Consent form which must be obtained prior to initiation of the study.
- The patient receives the catheter via the internal jugular or subclavian vein.
- All female patients of child bearing potential must complete a negative pregnancy test and will confirm that they are not breastfeeding.
Exclusion Criteria:
- The patient is participating in another IRB (Institutional Review Board) clinical trial, which modifies standard-of-care treatment and/or involves an investigational device or drug.
- The patient has a confirmed or suspected infection, bacteraemia or septicaemia.
- The patient's physiology is NOT suitable for placement of the NexSite device; this will include an examination of the anatomy at the proposed catheter exit site.
- The patient is known or suspected to have allergies to the materials used in the construction of the device.
- The patient has previously suffered from coagulation issues or has had vascular surgery at the proposed placement site.
- The patient has received radiation treatment at the proposed catheter placement site.
- The patient has severe chronic obstructive lung disease.
- The patient is pyretic within 72 hours (temperature ≥38o C or 100.4oF) prior to placement and/or has received antimicrobial drugs within two weeks prior to catheterisation.
- The patient is female of child bearing potential not using adequate contraception. (Adequate contraception is defined as abstinence, intrauterine device [IUD], birth control pills, or spermicidal gel with diaphragm or condom)
- The patient has another indwelling catheter.
- The patient has non-healing diabetic foot ulcers.
- The patient did not give informed consent.
- The patient would be unavailable for follow-up.
- The patient is a permanent nursing home resident.
- The proposed access site is not the internal jugular or subclavian vein.
- The patient is scheduled to undergo an elective surgical procedure (other than a procedure to create a graft or fistula) within the study timeframe.
- Any other condition that the Investigator believes should exclude the patient from the study.
- The patient does not have English or Spanish as their first language.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Altro
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: NexSite HD Patients
NexSite HD patient catheter device placement
|
Measurement of CRBSI rate and other device related adverse events in patients with NexSite HD Catheter.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of participants with Catheter-Related Blood Stream Infection (CRBSI)(bacteremia/fungemia) as an adverse event.
Lasso di tempo: Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
Number of participants with a confirmed CRBSI for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of participants with adverse events associated with device placement and use.
Lasso di tempo: Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
Number of participants with adverse events associated with device placement and for the duration of catheter use or to 180 days post device placement.
|
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
|
Number of participants with unhealed catheter exit sites
Lasso di tempo: Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
Number of participants with unhealed exit sites for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
|
Number of participants with tunnel infection as an adverse event
Lasso di tempo: Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
Number of participants with a tunnel infection for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
|
Number of participants with exit site infection as an adverse event
Lasso di tempo: Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
Number of participants with a exit site infection for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
|
Number of participants with Pneumothorax, haemothorax, arrhythmia, air embolism or arterial perforation as an adverse event.
Lasso di tempo: 1 day of device placement
|
Number of participants with non-infectious catheter complications within one day of placement.
|
1 day of device placement
|
|
Number of participants with Catheter dislodgement, Catheter tip dislodgement and catheter thrombosis as an adverse event.
Lasso di tempo: Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
Number of participants with late non infectious complications for the duration of catheter use or to 180 days post device placement (whichever occurs first).
|
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: Jeffrey G Hoggard, MD, Capital Nephrology Associates
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- TR 0147
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Malattia renale allo stadio terminale
-
NCT01807767RitiratoModello alto per il punteggio MELD (end-stage Liver Disease).
Prove cliniche su NexSite HD Patients
-
NCT01876485Completato
-
NCT02098798CompletatoMalattia infiammatoria intestinale
-
NCT07489131Reclutamento
-
NCT04577768Completato
-
NCT03319134Completato
-
NCT04932148Reclutamento
-
NCT06409143Reclutamento
-
NCT07370311ReclutamentoProcesso decisionale di fine vita | Caregivers di demenza | Demenza avanzata
-
NCT07184697Attivo, non reclutante